Form 10-Q BRISTOL MYERS SQUIBB CO For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Bristol-Myers (BMY) Bullish Stance Reiterated at BMO Capital Post Q1 and Ahead of ASCO Inflection for Opdivo
April 29, 2015 9:01 AM EDTBMO Capital analyst Alex Arfaei reiterated an Outperform rating and $75 on Bristol-Myers Squibb Co. (NYSE: BMY) following Q1 results and as ASCO should be an inflection point for Opdivo.
commented, "On the surface, 1Q looked solid: 6% topline beat, EPS $0.71 vs. $0.51. However, the Abilify beat is short-lived, and focus remains on the IO franchise. As we expected Yervoy sales were 6% below consensus, probably reflecting increased competition, and Opdivo sales... More
